Alzinova AB (publ) (OM: ALZ)
Health Care · Biotechnology · SE
Skr0.43
-1.96% today · -71.0% 1Y
Alzinova AB (publ) (OM: ALZ) operates in the Biotechnology industry within the Health Care sector. The company is valued at $13.21M and employs 7 people.
Over the last twelve months the share price has lost 71.0%, trading between 0.37 and 2.07.
Tweenvest scores Alzinova AB (publ) across four factors: quality 53/100, value 44/100, growth 82/100. Its strongest factor is growth.
ALZ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.21M
- Revenue (TTM)
- $15.37K
- P/E
- —
- EPS
- -0.20
- Dividend yield
- —
- Beta (5Y)
- 1.24
- 52-week high
- Skr2.07
- 52-week low
- Skr0.37
- Avg volume (3M)
- —
- Shares outstanding
- 307.49M
- Employees
- 7
- Next earnings
- —
About Alzinova AB (publ)
Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.
- ISIN
- SE0007413455
- Founded
- 2011
- Listed since
- Nov 25, 2015
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| BioCardia, Inc.NasdaqCM: BCDA | $13.93M | $0.92 | -11.53% |
| Imugene LimitedASX: IMU | $13.40M | AU$0.04 | +5.41% |
| Cerenome, Inc.NasdaqCM: CNSY | $13.28M | $1.75 | +1.16% |
| Genflow Biosciences plcLSE: GENF | $13.22M | £0.02 | -1.41% |
| Genomed Spólka AkcyjnaWSE: GEN | $13.14M | zł38.60 | -3.50% |
| Genomtec S.A.WSE: GMT | $12.72M | zł2.90 | -5.70% |
| Algorae Pharmaceuticals LimitedASX: 1AI | $12.70M | AU$0.01 | +12.50% |
| America Great HealthOTCPK: AAGH | $12.69M | $0.00 | +100.00% |
Figures last refreshed Oct 18, 2026.